Richard A. Cowell
Geen lopende functies
Profiel
Richard A.
Cowell served as an Independent Director at MicroVision, Inc. from 1996 to 2017, and at ImmunoCellular Therapeutics Ltd.
from 2007 to 2013.
He also worked as a Principal at Booz Allen Hamilton, Inc. from 1996 to 2011.
Cowell received his undergraduate degree from The Ohio State University.
Eerdere bekende functies van Richard A. Cowell
| Bedrijven | Functie | Einde |
|---|---|---|
| MICROVISION, INC. | Directeur/Bestuurslid | 07-06-2017 |
| EOM PHARMACEUTICALS HOLDINGS, INC. | Directeur/Bestuurslid | 30-09-2013 |
Booz Allen Hamilton, Inc.
 Booz Allen Hamilton, Inc. Engineering & ConstructionIndustrial Services Booz Allen Hamilton, Inc. engages in the provision of management and technology consulting services. Its services include consulting, analytics, digital solutions, engineering, cyber security, and product. The company was founded by Edwin G. Booz in 1914 and is headquartered in McLean, VA. | Corporate Officer/Principal | - |
Opleiding van Richard A. Cowell
| The Ohio State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MICROVISION, INC. | Electronic Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Booz Allen Hamilton, Inc.
Booz Allen Hamilton, Inc. Engineering & ConstructionIndustrial Services Booz Allen Hamilton, Inc. engages in the provision of management and technology consulting services. Its services include consulting, analytics, digital solutions, engineering, cyber security, and product. The company was founded by Edwin G. Booz in 1914 and is headquartered in McLean, VA. | Industrial Services |
ImmunoCellular Therapeutics Ltd.
 ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |
